Result description
The EDIT-B project led to the validation of the eponymous test, demonstrating sensitivity and specificity above 80% in an international clinical trial conducted across four centers in Spain, France, and Denmark, in collaboration with leading key opinion leaders. Including this study, the test has now been validated in a cohort of more than 800 patients in 3 independant clinical trials.
As a result, the EDIT-B test is now CE-marked, available in several European countries, and preparing for broad commercial deployment through an optimized market access strategy both within and beyond Europe.
Addressing target audiences and expressing needs
- Grants and Subsidies
- Business partners – SMEs, Entrepreneurs, Large Corporations
- Expanding to more markets /finding new customers
Public or private funding institutions: Grants and subsidies, other blended financing
Other Actors who can help us fulfil our market potential: Business partners – SMEs, Entrepreneurs, Large Corporations, Expanding to more markets /finding new customers
- Public or private funding institutions
- Other Actors who can help us fulfil our market potential
- Private Investors
R&D, Technology and Innovation aspects
In 2023 the EDIT-B consortium launched the test under the name myEDIT-B in Italy, two years’ ahead of schedule. In 2024 on World Bipolar Day, 30 March, myEDIT-B launched in France and and then in 2025 in Switzerland.
/
/
/
